{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:20Z","timestamp":1791765380159,"version":"4.3.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,13]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cilostazol is an antiplatelet drug and is used for stroke prevention and symptomatic peripheral vascular disease. Studies have reported the effects of cilostazol on cognitive function, but the results are inconsistent and have not been systematically assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We systematically searched the PubMed, Embase, and Cochrane databases for relevant clinical studies. The primary outcome was the change in Mini-mental State Examination (MMSE) scores from baseline to the last available follow-up. The secondary outcome was dementia risk. Mean differences and 95% confidence intervals (CIs) were calculated for combining MMSE scores, and the pooled odds ratios and 95% CIs were used to calculate the association between use of cilostazol and dementia risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 8 eligible studies met inclusion criteria were pooled in meta-analysis. Though with a trend toward favoring cilostazol, the pooled changes in MMSE scores from baseline showed no significant difference in mild cognitive impairment and dementia patients (mean differences 1.02, 95% CI \u22120.53 to 2.57, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.195). For secondary outcome, cilostazol reduced the risk of dementia in patients without prior history of dementia (pooled odds ratios 0.90; 95% CI 0.87 to 0.92; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.000).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>These results suggest the potential for cilostazol treatment in the suppression of cognitive decline and prevention of progression to dementia. However, the lack of blinding in most studies is likely to cause an overestimation of the effect sizes, and further well-designed studies are also needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040668","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T19:01:02Z","timestamp":1734375662000},"page":"e40668","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effects of cilostazol on cognitive function and dementia risk: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7987-6241","authenticated-orcid":false,"given":"Xiaofang","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifa","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusheng","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study.","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/archneurol.2009.106","article-title":"Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.","volume":"66","author":"Farias","year":"2009","journal-title":"Arch Neurol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.0b013e3181e8e8b8","article-title":"Comparing predictors of conversion and decline in mild cognitive impairment.","volume":"75","author":"Landau","year":"2010","journal-title":"Neurology"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcp.12511","article-title":"Angiotensin receptor blockers and risk of dementia: cohort study in UK clinical practice research datalink.","volume":"79","author":"Goh","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"Pt A","key":"R5-20250503","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer\u2019s disease: Past, present and future.","volume":"76 Pt A","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3233\/JAD-2009-0975","article-title":"Vascular factors in diabetes and Alzheimer\u2019s disease.","volume":"16","author":"Taguchi","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors.","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.brainres.2008.01.103","article-title":"Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats.","volume":"1203","author":"Fujita","year":"2008","journal-title":"Brain Res"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosissup.2005.09.005","article-title":"Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination.","volume":"6","author":"Comerota","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.300.2.709","article-title":"Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells.","volume":"300","author":"Kim","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/01.STR.20.5.668","article-title":"Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.","volume":"20","author":"Tanaka","year":"1989","journal-title":"Stroke"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1476-5381.2010.01014.x","article-title":"Cilostazol prevents amyloid beta peptide(25\u201335)-induced memory impairment and oxidative stress in mice.","volume":"161","author":"Hiramatsu","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2011.04.068","article-title":"Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation.","volume":"408","author":"Park","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jnr.23310","article-title":"Attenuation of beta-amyloid-induced tauopathy via activation of CK2alpha\/SIRT1: targeting for cilostazol.","volume":"92","author":"Lee","year":"2014","journal-title":"J Neurosci Res"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/psyg.12021","article-title":"Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis.","volume":"13","author":"Taguchi","year":"2013","journal-title":"Psychogeriatrics"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"e89516","DOI":"10.1371\/journal.pone.0089516","article-title":"Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.","volume":"9","author":"Ihara","year":"2014","journal-title":"PLoS One"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s13311-017-0512-4","article-title":"Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study.","volume":"14","author":"Tai","year":"2017","journal-title":"Neurotherapeutics"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"e12182","DOI":"10.1002\/trc2.12182","article-title":"Conversion from cilostazol to OPC-13015 linked to mitigation of cognitive impairment.","volume":"7","author":"Saito","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2023.1526","article-title":"Isosorbide mononitrate and cilostazol treatment in patients with symptomatic cerebral small vessel disease: the Lacunar Intervention Trial-2 (LACI-2) randomized clinical trial.","volume":"80","author":"Wardlaw","year":"2023","journal-title":"JAMA Neurol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"e12369","DOI":"10.1002\/trc2.12369","article-title":"Efficacy and safety of cilostazol in decreasing progression of cerebral white matter hyperintensities\u2014a randomized controlled trial.","volume":"8","author":"Ip","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"e2344938","DOI":"10.1001\/jamanetworkopen.2023.44938","article-title":"Efficacy and safety of cilostazol in mild cognitive impairment: a randomized clinical trial.","volume":"6","author":"Saito","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/STROKEAHA.120.029454","article-title":"Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis.","volume":"51","author":"McHutchison","year":"2020","journal-title":"Stroke"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state.\u201d A practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12883-017-0800-y","article-title":"Cilostazol as an add-on therapy for patients with Alzheimer\u2019s disease in Taiwan: a case control study.","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Neurol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3233\/JAD-170895","article-title":"Effect of cilostazol on incident dementia in elderly men and women with ischemic heart disease.","volume":"63","author":"Kim","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s13311-018-00708-x","article-title":"Efficacy of cilostazol administration in Alzheimer\u2019s disease patients with white matter lesions: a positron-emission tomography study.","volume":"16","author":"Lee","year":"2019","journal-title":"Neurotherapeutics"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"788407","DOI":"10.3389\/fnagi.2022.788407","article-title":"Anti-platelet therapy is associated with lower risk of dementia in patients with cerebral small vessel disease.","volume":"14","author":"Pan","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1381612820666140826114601","article-title":"Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer\u2019s disease: a translational overview.","volume":"21","author":"Heckman","year":"2015","journal-title":"Curr Pharm Des"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/JGP.0b013e31819431ea","article-title":"A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study.","volume":"17","author":"Arai","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/STROKEAHA.111.635417","article-title":"Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.","volume":"43","author":"Kasahara","year":"2012","journal-title":"Stroke"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/jscd.2001.24657","article-title":"Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction.","volume":"10","author":"Mochizuki","year":"2001","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1523\/JNEUROSCI.5291-04.2005","article-title":"Amyloid-beta peptide inhibits activation of the nitric oxide\/cGMP\/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity.","volume":"25","author":"Puzzo","year":"2005","journal-title":"J Neurosci"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/01.STR.0000221783.08037.a9","article-title":"Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion.","volume":"37","author":"Watanabe","year":"2006","journal-title":"Stroke"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2007.09.016","article-title":"Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats.","volume":"1185","author":"Lee","year":"2007","journal-title":"Brain Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:36:19Z","timestamp":1746318979000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":37,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040668","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}